The oral solid dosage pharmaceutical formulation market is projected to achieve US$ 8,95,636.0 million by 2034, up from its estimated US$ 6,29,582.6 million in 2024. Market dynamics of oral solid dosage pharmaceutical formulations are primarily influenced by factors such as the expanding elderly population that needs long-term pharmaceutical treatment, the progress of drug formulation technologies, and the growing demand for oral pharmaceuticals.
Between 2024 and 2034, the oral solid dosage pharmaceutical formulation market is anticipated to advance at a CAGR of 3.7%. Drug administration technologies have seen significant innovation in the oral solid dosage pharmaceutical formulation industry, increasing patient compliance and efficacy. The market opportunity of oral solid dosage pharmaceutical formulation to develop and change in response to the constantly changing healthcare environment.
| Attributes | Details |
|---|---|
| Market Value for 2024 | US$ 6,29,582.6 million |
| Market Value for 2034 | US$ 8,95,636.0 million |
| Market CAGR from 2024 to 2034 | 3.7% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Continuous developments in pharmaceutical production technology, such as novel equipment and methods, aid in the creation of oral solid dosage formulations that are more economical and efficient. These developments accelerate oral solid dosage pharma formulation market expansion by improving the pharmaceutical products' quality, safety, and repeatability.
Market dynamics are influenced by patients' preference for oral drugs, which are motivated by familiarity with and convenience in usage. Consumers are accepting oral solid dosage forms, which fosters oral solid dosage pharmaceutical formulation industry expansion.
The aging of the global population is increasing the prevalence of chronic illnesses. The pharmaceutical industry is expanding due to a growing demand for oral solid dosage forms that address chronic diseases.
| Attributes | Details |
|---|---|
| Market Value for 2019 | US$ 6,29,582.6 million |
| Market Value for 2023 | US$ 6,29,582.6 million |
| Market CAGR from 2019 to 2023 | 2.8% |
Complex facilities, sophisticated machinery, and knowledgeable workers are required to produce oral solid dosage forms. Smaller pharmaceutical companies are barriers to entry due to high initial capital investment and continuous operating costs associated with production facilities.
Government policies that support generic replacement and cost-cutting efforts in healthcare systems negatively impact the oral solid dose pharmaceutical formulation market. Policies that require or reward generic replacement pressure prices and diminish the market share of branded goods.
Principal Consultant
The segmented oral solid dosage pharmaceutical formulation market analysis is included in the following subsection. Based on comprehensive research, the immediate release sector is controlling the drug release mechanism category, and the tablets segment dominates the dosage form category.
| Segment | Immediate Release |
|---|---|
| Share (2024) | 43.30% |
Immediate release drugs are more convenient and increase patient compliance, which boosts sales of oral solid dosage pharmaceutical formulations. Evident in prescribers' general preference for first-line therapies is the dominance of immediate release segment.
Given their applicability across a range of therapeutic domains, the immediate release segment continues to enjoy substantial demand for oral solid dosage pharmaceutical formulation. Easy administration and flexible dosage schedules are two factors supporting immediate release formulations' ongoing prominence in the oral solid dose pharmaceutical formulation market.
| Segment | Tablets |
|---|---|
| Share (2024) | 48.90% |
Due to their affordability, patient familiarity, and manufacturing convenience, tablets account for the majority of sales of oral solid dosage pharmaceutical formulation. Even with many alternatives, the oral solid dosage pharmaceutical formulation industry favors tablets as a reliable, effective, and commonly recognized dosage form.
Then, follow capsules, which are more adaptable and have better drug stability, making them suitable for various formulations. Powders and granules, particularly in formulations for children and the elderly, are prevalent for individualized dosing.
Pastilles and lozenges target specific therapeutic areas and are prized for their targeted distribution and ability to increase patient compliance. Gummies are a growing trend that draws consumers looking for new and tasty substitutes, propelling the nutraceutical industry's growth.
The oral solid dosage pharmaceutical formulation market can be observed in the subsequent tables, which focus on the leading regions in North America, Europe, and Asia Pacific. A comprehensive evaluation demonstrates that Asia Pacific has enormous market opportunities for oral solid dosage pharmaceutical formulation.
Oral Solid Dosage Pharma Formulation Opportunities in Asia Pacific
| Countries | CAGR (2024 to 2034) |
|---|---|
| China | 7.2% |
| South Korea | 6.8% |
| Japan | 3.3% |
Given its size and changing regulatory environment, China offers many opportunities for oral solid dosage pharmaceutical formulations. The increasing emphasis on healthcare accessibility and the rising demand for oral solid dosage forms promote China's pharmaceutical industry's rapid expansion. Advancements in manufacturing and new technology are fostering China's oral solid dosage pharma formulation market expansion.
The market is expanding owing to the South Korean government's encouraging policies and investments in research and development facilities. South Korea is a desirable center for the regional manufacture and export of oral solid dosage formulations due to its advantageous location and robust intellectual property protection.
Technology and manufacturing process developments are continually raising the productivity and competitiveness of the South Korean oral solid dosage pharmaceutical formulation industry.
Innovation in oral solid dosage pharmaceutical formulations is in high demand in Japan due to the country's aging population and rising rates of chronic diseases. Oral solid dose forms are developed under the influence of Japan's pharmaceutical industry, distinguished by an emphasis on tailored medicines and precision medicine.
Japan's oral solid dose pharmaceutical formulation market experiences innovation caused by ongoing investment in research and development and advances in manufacturing technology.
Market Growth Analysis of Oral Solid Dosage Pharma Formulation in Europe
| Countries | CAGR (2024 to 2034) |
|---|---|
| France | 4.6% |
| Italy | 3.8% |
| Spain | 2.7% |
| United Kingdom | 2.1% |
| Germany | 1.6% |
Strict laws controlling oral solid dose pharmaceuticals result from the French market's emphasis on quality and safety standards. Specialized oral solid dose formulations suited to geriatric healthcare needs are in high demand due to France's aging population. The French government's healthcare policies aim to ensure that oral solid dosage pharmaceuticals are widely available to the general public.
Naturally occurring oral solid dose formulations are strongly affected by the rich history of herbal therapy that Italy's pharmaceutical industry has enjoyed. Italians place a high priority on preventative healthcare, which ignites the oral solid dosage pharma formulation market that addresses illnesses related to lifestyle, like metabolic disorders.
Producers of oral solid dosage pharmaceutical formulation prioritize cost-effective oral solid dosage formulations without sacrificing quality in the Spanish market, where pricing is an integral factor. Spain's regulatory framework supports environmentally sustainable approaches in the manufacturing of oral solid doses.
Collaborative efforts between Spanish pharmaceutical companies and research institutions facilitate the creation of innovative oral solid dose formulations for rare illnesses.
The development of customized oral solid dosage formulations based on genetic profiles is stimulated by the United Kingdom pharmaceutical market's emphasis on personalized medicine. To meet healthcare demands at a reasonable cost, the National Health Service (NHS) in the United Kingdom is a major influence on developments in oral solid dose formulation.
Sustained-release formulations and other innovative oral solid dose formulation technologies are made possible by Germany's substantial expenditure on research and development. The German healthcare system has influenced the creation of user-friendly oral solid dosage formulations with clear dosing instructions, which promotes patient education and self-management.
Market Dynamics of Oral Solid Dosage Pharmaceutical Formulation in North America
| Countries | CAGR (2024 to 2034) |
|---|---|
| Canada | 2.8% |
| United States | 1.7% |
In the United States, advances in oral solid dosage pharmaceutical formulations are stimulated by the rising need for generic medications and the growing emphasis on individualized therapy. The United States' oral solid dosage pharmaceutical production landscape is changing due to the emergence of contract manufacturing organizations, or CMOs.
The Canada oral solid dosage pharmaceutical formulations market witnessed an increased demand for user-friendly formulations due to consumers' growing preference for over-the-counter pharmaceuticals. In Canada, particularly in rural areas, the rise of e-pharmacies and telemedicine is opening up fresh pathways for oral solid dosage pharmaceutical delivery and accessibility.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
With their knowledge and inventiveness, key oral solid dosage pharmaceutical formulation vendors rule the market in the fiercely competitive field. These oral solid dosage pharmaceutical formulation producers advance the development of pharmaceutical formulations by contributing various strengths. Pfizer, Novartis, and AstraZeneca are renowned for their broad product lines and dedication to innovation.
Merck, Eli Lilly, and AbbVie are proficient in particular therapeutic domains, augmenting the market's products. Johnson & Johnson and Teva Pharmaceuticals are important contributors to the accessibility and affordability of oral solid dosage pharmaceutical formulations.
In this highly competitive environment, oral solid dosage pharmaceutical formulation providers constantly strive to bring novel formulations, better drug delivery systems, and improve patient outcomes through ongoing research and development activities. Supply chain management, quality control, and regulatory compliance are still essential for preserving the market competitiveness of oral solid dosage pharmaceutical formulation.
The dynamic competition in the market compels oral solid dosage pharmaceutical formulation manufacturers to innovate, provide high-quality products and services, and prioritize accessibility in response to changing healthcare requirements.
Latest Advancements
| Company | Details |
|---|---|
| Catalent | In February 2023, Catalent paid US$475 million to purchase Metrics Contract Services to increase its production capacity for oral solid dose and high-potency pharmaceuticals. |
| Pfizer | In March 2023, Pfizer introduced Lyrica (pregabalin) in a new extended-release tablet format for the treatment of neuropathic pain. |
| Eli Lilly & Company | Eli Lilly & Company announced the release of Trulicity, a novel bilayer tablet formulation intended to treat type 2 diabetes, in April 2023. |
| Farxiga | The new once-daily oral tablet version of Farxiga for the treatment of type 2 diabetes and heart failure with maintained ejection fraction was announced by AstraZeneca plc in May 2023. |
| Novartis AG | Novartis AG announced in June 2023 the launch of its new extended-release Vytorin tablet formulation for treating high cholesterol. |
The oral solid dosage pharmaceutical formulation industry to possess a valuation US$ 6,29,582.6 million in 2024.
The oral solid dosage pharmaceutical formulation industry is estimated to hit a worth of US$ 8,95,636.0 million by 2034.
Through 2034, the oral solid dosage pharmaceutical formulation industry is anticipated to spur at a sluggish CAGR of 3.7%.
From 2019 to 2023, the oral solid dosage pharmaceutical formulation industry registered a 2.8% HCAGR.
The immediate release sector is scheduled to garner a share of 43.3% in 2024.
A 48.9% market share is expected for the tablets sector in 2024.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Manufacturer
3.5.1.2. Mid-Level Participants (Traders)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Dosage Form
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Dosage Form, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Dosage Form, 2024 to 2034
5.3.1. Tablets
5.3.1.1. Conventional/Immediate Release
5.3.1.2. Modified Release
5.3.1.3. Chewable Tablets
5.3.1.4. Effervescent Tablets
5.3.2. Capsules
5.3.2.1. Hard Gelatin Capsules
5.3.2.2. Soft Gelatin Capsules
5.3.2.3. Others
5.3.3. Powders & Granules
5.3.4. Lozenges & Pastilles
5.3.5. Gummies
5.4. Y-o-Y Growth Trend Analysis By Dosage Form, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Dosage Form, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Release Mechanism
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Drug Release Mechanism, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Drug Release Mechanism, 2024 to 2034
6.3.1. Immediate Release
6.3.2. Delayed Release
6.3.3. Controlled Release
6.4. Y-o-Y Growth Trend Analysis By Drug Release Mechanism, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Drug Release Mechanism, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Drug Stores
7.3.4. Online Pharmacies
7.3.5. Hypermarkets/Supermarkets
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023
8.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
9.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
9.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Dosage Form
9.2.3. By Drug Release Mechanism
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Dosage Form
9.3.3. By Drug Release Mechanism
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Dosage Form
10.2.3. By Drug Release Mechanism
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Dosage Form
10.3.3. By Drug Release Mechanism
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Dosage Form
11.2.3. By Drug Release Mechanism
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Dosage Form
11.3.3. By Drug Release Mechanism
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Dosage Form
12.2.3. By Drug Release Mechanism
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Dosage Form
12.3.3. By Drug Release Mechanism
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Dosage Form
13.2.3. By Drug Release Mechanism
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Dosage Form
13.3.3. By Drug Release Mechanism
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Dosage Form
14.2.3. By Drug Release Mechanism
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Dosage Form
14.3.3. By Drug Release Mechanism
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Dosage Form
15.2.3. By Drug Release Mechanism
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Dosage Form
15.3.3. By Drug Release Mechanism
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2023
16.1.2.1. By Dosage Form
16.1.2.2. By Drug Release Mechanism
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2023
16.2.2.1. By Dosage Form
16.2.2.2. By Drug Release Mechanism
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2023
16.3.2.1. By Dosage Form
16.3.2.2. By Drug Release Mechanism
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2023
16.4.2.1. By Dosage Form
16.4.2.2. By Drug Release Mechanism
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2023
16.5.2.1. By Dosage Form
16.5.2.2. By Drug Release Mechanism
16.5.2.3. By Distribution Channel
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2023
16.6.2.1. By Dosage Form
16.6.2.2. By Drug Release Mechanism
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2023
16.7.2.1. By Dosage Form
16.7.2.2. By Drug Release Mechanism
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2023
16.8.2.1. By Dosage Form
16.8.2.2. By Drug Release Mechanism
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2023
16.9.2.1. By Dosage Form
16.9.2.2. By Drug Release Mechanism
16.9.2.3. By Distribution Channel
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2023
16.10.2.1. By Dosage Form
16.10.2.2. By Drug Release Mechanism
16.10.2.3. By Distribution Channel
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2023
16.11.2.1. By Dosage Form
16.11.2.2. By Drug Release Mechanism
16.11.2.3. By Distribution Channel
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2023
16.12.2.1. By Dosage Form
16.12.2.2. By Drug Release Mechanism
16.12.2.3. By Distribution Channel
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2023
16.13.2.1. By Dosage Form
16.13.2.2. By Drug Release Mechanism
16.13.2.3. By Distribution Channel
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2023
16.14.2.1. By Dosage Form
16.14.2.2. By Drug Release Mechanism
16.14.2.3. By Distribution Channel
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2023
16.15.2.1. By Dosage Form
16.15.2.2. By Drug Release Mechanism
16.15.2.3. By Distribution Channel
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2023
16.16.2.1. By Dosage Form
16.16.2.2. By Drug Release Mechanism
16.16.2.3. By Distribution Channel
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2023
16.17.2.1. By Dosage Form
16.17.2.2. By Drug Release Mechanism
16.17.2.3. By Distribution Channel
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2023
16.18.2.1. By Dosage Form
16.18.2.2. By Drug Release Mechanism
16.18.2.3. By Distribution Channel
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2023
16.19.2.1. By Dosage Form
16.19.2.2. By Drug Release Mechanism
16.19.2.3. By Distribution Channel
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2023
16.20.2.1. By Dosage Form
16.20.2.2. By Drug Release Mechanism
16.20.2.3. By Distribution Channel
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2023
16.21.2.1. By Dosage Form
16.21.2.2. By Drug Release Mechanism
16.21.2.3. By Distribution Channel
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2023
16.22.2.1. By Dosage Form
16.22.2.2. By Drug Release Mechanism
16.22.2.3. By Distribution Channel
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2023
16.23.2.1. By Dosage Form
16.23.2.2. By Drug Release Mechanism
16.23.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Dosage Form
17.3.3. By Drug Release Mechanism
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. AstraZeneca Plc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.1.5.2. Product Strategy
18.1.1.5.3. Channel Strategy
18.1.2. Bristol-Myers Squibb Company
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.2.5.2. Product Strategy
18.1.2.5.3. Channel Strategy
18.1.3. Eli Lilly and Company
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.3.5.2. Product Strategy
18.1.3.5.3. Channel Strategy
18.1.4. Gilead Sciences
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.4.5.2. Product Strategy
18.1.4.5.3. Channel Strategy
18.1.5. Merck & Co. Inc
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.5.5.2. Product Strategy
18.1.5.5.3. Channel Strategy
18.1.6. Novartis AG
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.6.5.2. Product Strategy
18.1.6.5.3. Channel Strategy
18.1.7. Pfizer Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.7.5.2. Product Strategy
18.1.7.5.3. Channel Strategy
18.1.8. AbbVie Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.8.5.2. Product Strategy
18.1.8.5.3. Channel Strategy
18.1.9. Boehringer Ingelheim GmbH
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.9.5.2. Product Strategy
18.1.9.5.3. Channel Strategy
18.1.10. F. Hoffman-La-Roche Ltd.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.10.5.2. Product Strategy
18.1.10.5.3. Channel Strategy
18.1.11. Johnson & Johnson
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.11.5.2. Product Strategy
18.1.11.5.3. Channel Strategy
18.1.12. Biogen Inc.
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
18.1.12.5.2. Product Strategy
18.1.12.5.3. Channel Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Healthcare
July 2023
REP-GB-17655
250 pages
Explore Healthcare Insights
View Reports
Oral Solid Dosage Pharmaceutical Formulation Market
